Schroder Investment Management Group Cytom X Therapeutics, Inc. Transaction History

Schroder Investment Management Group

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2018 Feb 14, 2019	SELL	$12.69 - $18.61 $30,024 - $44,031	-2,366 Closed	0 $0
Q3 2018 Nov 13, 2018	BUY	$18.04 - $26.41 $42,682 - $62,486	2,366 New	2,366 $44,000
Q2 2018 Aug 13, 2018	SELL	$21.38 - $29.68 $909,633 - $1.26 Million	-42,546 Closed	0 $0
Q1 2018 May 11, 2018	SELL	$21.76 - $34.22 $802,748 - $1.26 Million	-36,891 Reduced 46.44%	42,546 $1.21 Million
Q4 2017 Feb 09, 2018	BUY	$19.0 - $23.09 $994,612 - $1.21 Million	52,348 Added 193.24%	79,437 $1.68 Million
Q3 2017 Nov 09, 2017	BUY	$13.53 - $18.17 $366,514 - $492,207	27,089	27,089 $489,000

49.4M

112K

8.3K

Ticker CTMX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,950,200
Market Cap $55.4M
Description
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...

Get notified when there are updates to the investment portfolio of Schroder Investment Management Group, based on Form 13F filings with the SEC.

Stay updated on Schroder Investment Management Group with notifications on news.